Clinical Trials Browser

Active not recruiting × Has results × Has announcements × Clear all

NCT03653507 2026-04-17

GLOW

Phase 3 Active not recruiting

507 enrolled 65 charts 3 FDA

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT03157128 2026-04-16

LIBRETTO-001

Phase 1/2 Active not recruiting

857 enrolled 24 charts 6 FDA

BreastCNSEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Medullary

NCT01946204 2026-04-13

SPARTAN

Phase 3 Active not recruiting

1,207 enrolled 15 charts 2 FDA

Prostatic Neoplasms

NCT02365597 2026-04-13

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Phase 2 Active not recruiting

239 enrolled 32 charts 2 FDA

Urothelial Cancer

NCT02489318 2026-04-13

TITAN

Phase 3 Active not recruiting

1,052 enrolled 13 charts 2 FDA

Prostatic Neoplasms

NCT02864992 2026-04-13

VISION

Phase 2 Active not recruiting

337 enrolled 13 charts 4 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03301220 2026-04-13

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Phase 3 Active not recruiting

390 enrolled 12 charts 3 FDA

Smoldering Multiple Myeloma

NCT03375320 2026-04-13

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Phase 3 Active not recruiting

298 enrolled 14 charts 3 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03390504 2026-04-13

THOR

Phase 3 Active not recruiting

629 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT03748641 2026-04-13

MAGNITUDE

Phase 3 Active not recruiting

765 enrolled 16 charts 2 FDA

Prostatic Neoplasms, Castration-Resistant

NCT03907488 2026-04-13

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Phase 3 Active not recruiting

994 enrolled 11 charts 2 FDA

Hodgkin Disease

NCT03914612 2026-04-13

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Phase 3 Active not recruiting

813 enrolled 16 charts 2 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT04497844 2026-04-13

AMPLITUDE

Phase 3 Active not recruiting

696 enrolled 15 charts 3 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT04538664 2026-04-13

PAPILLON

Phase 3 Active not recruiting

308 enrolled 12 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT05388669 2026-04-13

PALOMA-3

Phase 3 Active not recruiting

418 enrolled 16 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04099251 2026-04-09

CheckMate76K

Phase 3 Active not recruiting

790 enrolled 18 charts 2 FDA

Melanoma

NCT03652064 2026-04-08

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Phase 3 Active not recruiting

395 enrolled 11 charts 3 FDA

Multiple Myeloma

NCT03962543 2026-04-08

ReNeu

Phase 2 Active not recruiting

114 enrolled 25 charts 3 FDA

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT03395197 2026-04-07

TALAPRO-2

Phase 3 Active not recruiting

1,054 enrolled 21 charts 2 FDA

mCRPC

NCT04971226 2026-04-06

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Phase 3 Active not recruiting

405 enrolled 18 charts 3 FDA

MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02511106 2026-03-30

ADAURA

Phase 3 Active not recruiting

682 enrolled 20 charts 3 FDA

Stage IB-IIIA Non-small Cell Lung Carcinoma

NCT04656652 2026-03-24

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

Phase 3 Active not recruiting

605 enrolled 14 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT04689828 2026-03-23

PSMAfore

Phase 3 Active not recruiting

469 enrolled 11 charts 3 FDA

Prostatic Neoplasms

NCT04924608 2026-03-23

KOMET

Phase 3 Active not recruiting

145 enrolled 17 charts 3 FDA

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03298451 2026-03-20

HIMALAYA

Phase 3 Active not recruiting

1,324 enrolled 31 charts 2 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT05059262 2026-03-20

MOTION

Phase 3 Active not recruiting

123 enrolled 19 charts 3 FDA

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT03875235 2026-03-19

TOPAZ-1

Phase 3 Active not recruiting

810 enrolled 24 charts 2 FDA

Gastrointestinal

Biliary Tract Neoplasms

NCT04211337 2026-03-19

LIBRETTO-531

Phase 3 Active not recruiting

291 enrolled 16 charts 3 FDA

Carcinoma, Medullary

NCT02166463 2026-03-17

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

Phase 3 Active not recruiting

600 enrolled 14 charts 1 FDA

Ann Arbor Stage IIB Hodgkin Lymphoma

NCT04191499 2026-03-17

INAVO120

Phase 2/3 Active not recruiting

325 enrolled 14 charts 3 FDA

Breast Neoplasms

NCT04710576 2026-03-16

AGAVE-201

Phase 2 Active not recruiting

241 enrolled 11 charts 3 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT03164616 2026-03-13

POSEIDON

Phase 3 Active not recruiting

1,186 enrolled 26 charts 2 FDA

Non Small Cell Lung Cancer NSCLC

NCT03732677 2026-03-13

NIAGARA

Phase 3 Active not recruiting

1,063 enrolled 15 charts 3 FDA

Urinary Bladder Neoplasms

NCT02655016 2026-03-10

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Phase 3 Active not recruiting

733 enrolled 21 charts 3 FDA

Ovarian Neoplasms

NCT05091567 2026-03-10

IMforte

Phase 3 Active not recruiting

660 enrolled 23 charts 3 FDA

Small Cell Lung Carcinoma

NCT03336333 2026-03-09

SEQUOIA

Phase 3 Active not recruiting

590 enrolled 12 charts 2 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05116189 2026-03-09

KEYNOTE-B96

Phase 3 Active not recruiting

643 enrolled 17 charts 3 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03036098 2026-03-06

CheckMate901

Phase 3 Active not recruiting

1,314 enrolled 23 charts 2 FDA

Urothelial Cancer

NCT02362594 2026-03-05

MK-3475-054

Phase 3 Active not recruiting

1,019 enrolled 16 charts 2 FDA

Melanoma

NCT04494425 2026-03-04

DB-06

Phase 3 Active not recruiting

866 enrolled 25 charts 3 FDA

Breast Neoplasms

NCT03521154 2026-02-27

LAURA

Phase 3 Active not recruiting

216 enrolled 25 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT02811861 2026-02-23

CLEAR

Phase 3 Active not recruiting

1,069 enrolled 12 charts 2 FDA

Carcinoma, Renal Cell

NCT02032823 2026-02-17

OlympiA

Phase 3 Active not recruiting

1,836 enrolled 20 charts 2 FDA

Breast Neoplasms

NCT03504397 2026-02-13

Spotlight

Phase 3 Active not recruiting

565 enrolled 63 charts 3 FDA

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT04711135 2026-02-12

NETTER-P

Phase 2 Active not recruiting

11 enrolled 14 charts 2 FDA

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT02213926 2026-02-10

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Phase 2 Active not recruiting

124 enrolled 10 charts 2 FDA

Lymphoma, Mantle-Cell

NCT03710603 2026-02-10

Perseus

Phase 3 Active not recruiting

709 enrolled 17 charts 2 FDA

Multiple Myeloma

NCT02970318 2026-02-06

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Phase 3 Active not recruiting

310 enrolled 18 charts 2 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04044768 2026-02-06

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

52 enrolled 15 charts 1 FDA

Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT02486718 2026-02-05

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Phase 3 Active not recruiting

1,280 enrolled 24 charts 2 FDA

Carcinoma, Non-Small-Cell Lung